top of page

A GUIDING LIGHT IN EARLY DISEASE DETECTION

IMMUNOFLUORESCENCE

Sensitive detection of multiple biological targets simultaneously.​​​                   â€‹

Luminspheres™â€‹â€‹ being several orders of magnitude brighter than molecular fluorophores and multicolours fluorescing simultaneously permits direct concurrent immunofluorescent staining and imaging of multiple biological targets in a single sample.

fluorescent cells.png

​DRACS

Digital Rapid Autonomous Cancer Screening (DRACS™) is revolutionising the early detection of cancer from a liquid biopsy.    

​

Luminspheres stained Circulating Tumour Cells (CTCs) present in a blood sample are detected by high-throughput digital analysis and counted by software that supports diagnosis.

HER2 ULTRA-LOW DETECTION

Ultra-sensitive IHC HER2 detection identifies breast cancer patients that could benefit antibody-drug conjugate therapy.

​​​​

Luminspheres™ extraordinary brightness can detect ultra-low levels of HER2 present in tissue graded HER2-0.  ​A high-throughput digital scanner images any Luminspheres™ stained HER2 present and  software stratifies HER2-ultralow and HER2-null to support  diagnosis and  treatment selection.

image_edited.jpg

CRISPR

LAFreader.png

CRISPR powered detection that enables rapid point of care genomic testing.​​​​

​

The presence of target RNA results in a concomitant increase in bright green Luminspheres Reporter signal that can be detected quantitatively in a laboratory setting or at point of care by lateral flow.​​​​

bottom of page